Xu Li Jun, Wang Yan Yan, Zheng Xiao Dong, Gui Xiang Dong, Tao Li Feng, Wei Hai Ming
Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
Cell Mol Immunol. 2009 Feb;6(1):67-72. doi: 10.1038/cmi.2009.9.
Tuberculosis remains the worldwide infectious disease. To identify the therapeutic potential of M. vaccae in treating tuberculosis, M. vaccae was injected into Mycobacterium tuberculosis (M. tuberculosis) infected mice. The optimal dose of M. vaccae (22.5 microg/mouse) treated mice showed lower pathological change index, spleen weight index, lung weight index and vital M. tuberculosis count than those of the untreated group. Treatment with M. vaccae enhanced the percentages of CD3+ and CD4+ T cells, IFN-gamma+CD4+ T cells, innate immune cells including NK cells, NK1.1+ T cells and gammadeltaT cells, and reduced the percentage of IL-4+CD4+ T cells. Therefore, M. vaccae could protect the mice from M. tuberculosis infection and improve mouse innate and adaptive cell-mediated immunity, suggesting that M. vaccae is a potential immunotherapeutic agent in pulmonary tuberculosis.
结核病仍然是一种全球性的传染病。为了确定母牛分枝杆菌在治疗结核病方面的治疗潜力，将母牛分枝杆菌注射到感染结核分枝杆菌的小鼠体内。用最佳剂量（22.5微克/小鼠）的母牛分枝杆菌治疗的小鼠，其病理变化指数、脾脏重量指数、肺脏重量指数和活结核分枝杆菌数量均低于未治疗组。母牛分枝杆菌治疗可提高CD3 +和CD4 + T细胞、IFN-γ+ CD4 + T细胞以及包括NK细胞、NK1.1 + T细胞和γδT细胞在内的先天免疫细胞的百分比，并降低IL-4 + CD4 + T细胞的百分比。因此，母牛分枝杆菌可以保护小鼠免受结核分枝杆菌感染，并改善小鼠的先天和适应性细胞介导免疫，这表明母牛分枝杆菌是一种潜在的肺结核免疫治疗药物。
